PubMed Health⌕ Search

Biomedical subjects

G M Yuill

Publications and source records attributed to G M Yuill.

35 records · Page 2Linked to original sources
PubMed1976

Abetalipoproteinaemia. A case report with pathological studies.

The clinical and pathological features of a case of abetalipoproteinaemia in a 38-year-old patient are described in detail. A feature not previously recorded was a marked reduction in the velocity of ocular horizontal saccadic movements. Pathological studies revealed an active chronic demyelinating process. The patient showed no response to large doses of vitamin E. The rationale for this therapy, and the possible reasons for its failure are discussed.

Abetalipoproteinemia↗
PubMed1974

Congenital non-progressive peripheral neuropathy with arthrogryposis multiplex.

A family is described in which a hereditary peripheral neuropathy occurs, inherited as an autosomal dominant character. The syndrome is present at birth and does not show any significant progression thereafter. Three of the cases have suffered from arthrogryposis multiplex congenita. A secondary myopathy is also present. The condition appears to be intermediary between peroneal muscular atrophy and Friedreich's ataxia. Appearance at birth, presence of arthrogryposis multiplex congenita, and the non-progressive nature separate it sharply from the other heredofamilial ataxias and peripheral neuropathies.

Adult↗
PubMed1974

Benefit from adrenocorticotrophin in myasthenia gravis.

Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course of injections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.

Adolescent↗
PubMed1973

Interactions of L-dopa and amantadine in patients with Parkinsonism.

Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine. Each drug was given for six weeks, and six weeks were allowed to elapse between the two periods of treatment. Marked improvement occurred in patients given L-dopa first, whereas no clinical effect was observed in those patients treated first with amantadine. L-dopa was less beneficial to patients who had previously received amantadine, whereas amantadine became effective in patients who had previously taken L-dopa. The effect of pre-treatment with one drug on the therapeutic effectiveness of the other drug is reflected in changes of homovanillic acid levels in the cerebrospinal fluid.

Amantadine↗